Actinogen Medical Limited

Jul 22, 2025

A novel oral treatment for Alzheimer's: Actinogen's pivotal trial currently recruiting participants in the US

Jun 30, 2025

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline

Feb 12, 2025

Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal

Dec 09, 2024

Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial

Aug 26, 2024

Actinogen announces further positive results on depression in the XanCIDD phase 2a trial

Aug 12, 2024

Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial

Jun 26, 2024

Positive Xanamem® biomarker trial published in the Journal of Alzheimer's Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau

Apr 22, 2024

Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial

Apr 15, 2024

First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial